Skip to Content
Merck
All Photos(1)

Documents

Y0001002

Tetracaine for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Tetracaine hydrochloride, 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester, Amethocaine hydrochloride

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C15H24N2O2 · HCl
CAS Number:
Molecular Weight:
300.82
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

tetracaine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl.CCCCNc1ccc(cc1)C(=O)OCCN(C)C

InChI

1S/C15H24N2O2.ClH/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3;/h6-9,16H,4-5,10-12H2,1-3H3;1H

InChI key

PPWHTZKZQNXVAE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Topical ophthalmic anesthetic; used for spinal anesthesia

Biochem/physiol Actions

Blocks voltage-sensitive release of Ca2+ from sarcoplasmic reticulum.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - STOT SE 3

Target Organs

Central nervous system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Helen Giannakopoulos et al.
Journal of the American Dental Association (1939), 143(8), 872-880 (2012-08-03)
The authors evaluated the cardiovascular effects and pharmacokinetics of an intranasal 3 percent tetracaine/0.05 percent oxymetazoline spray developed to provide needle-free anesthesia of maxillary teeth. The authors administered to 12 participants a proposed maximum recommended dose (MRD) (18 milligrams tetracaine/0.3
Thomas B Marriott et al.
Clinical therapeutics, 34(10), 2174-2183 (2012-09-05)
The lidocaine/tetracaine heated patch is typically applied to the skin for 20 to 30 minutes to provide local dermal analgesia prior to venous access or minor dermatologic procedures. The potential exists for the use of multiple heated patches for longer
Patrick E McCleskey et al.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 39(1 Pt 1), 82-91 (2013-01-03)
Few published studies have analyzed serum lidocaine levels and individual patient characteristics affecting metabolism after application of compounded topical anesthetics. To measure serum lidocaine levels during and cutaneous side effects after standardized application of 23% lidocaine/7% tetracaine compounded anesthetic to
Gabriel C Gaviola et al.
The Laryngoscope, 123(4), 852-858 (2013-02-14)
Transnasal endoscopy is commonly performed in an outpatient otolaryngology setting. Patients are typically administered a topical anesthetic and decongestant prior to this procedure to alleviate discomfort and improve visualization. There is no consensus on which topical anesthetic is most effective
Quan Wen et al.
Cornea, 32(2), 179-184 (2012-08-08)
Our recent tissue cross-linking studies have raised the possibility of using aliphatic β-nitroalcohols (BNAs) for pharmacologic, therapeutic corneal cross-linking. The present study was performed to determine the permeability of BNAs and to explore the use of permeability-enhancing agents. Ex vivo

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service